VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
seliciclib
Phase 2
Small molecule
C
Cyclacel Pharmaceuticals, Inc.
1
Indications
3
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cushing Disease
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cushing Disease
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Breast Cancer
1 trial
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Withdrawn
·
M
M.D. Anderson Cancer Center
·
Phase 1
·
NCT01333423
Non-Small Cell Lung Cancer
1 trial
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Terminated
·
C
Cyclacel Pharmaceuticals, Inc.
·
Phase 2
·
NCT00372073
·
187 enrolled
Cushing Disease
1 trial
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Recruiting
·
—
·
Phase 2
·
NCT03774446
·
13 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for seliciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
seliciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for seliciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Cyclacel Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
C
Cyclacel Pharmaceuticals, Inc.
Related News